Foundayo®
The first oral GLP-1 pill for weight management
About Foundayo®
Foundayo® (orforglipron) is an oral, once-daily GLP-1 receptor agonist approved by the FDA in April 2026 — the first GLP-1 pill cleared for chronic weight management in adults. As a small-molecule tablet rather than a peptide, it can be taken any time of day with or without food or water restrictions, and it does not require refrigeration. Foundayo® works through the same GLP-1 pathway as injectable GLP-1 medications: reducing appetite, slowing gastric emptying, and supporting healthier eating patterns over time.
Common reasons patients ask about Foundayo:
- Once-daily oral pill — no injections, no refrigeration
- Taken at any time of day, with or without food or water
- Reduced appetite and fewer cravings
- Steady weight loss alongside lifestyle changes
Data
What the studies show
Foundayo® was studied in Eli Lilly's ATTAIN and ACHIEVE phase 3 programs. The ATTAIN program evaluated orforglipron for chronic weight management; at the highest doses, completers averaged roughly 12% body weight reduction along with improvements in waist circumference, cholesterol, triglycerides, and systolic blood pressure. ACHIEVE-3 compared orforglipron to oral semaglutide in adults with type 2 diabetes inadequately controlled by metformin, with orforglipron producing greater weight loss and glycemic control.
~12%
Average body weight reduction at the highest dose among ATTAIN completers
ATTAIN
Pivotal phase 3 weight-management program
2026
Year of FDA approval for chronic weight management
How it works
Regulates appetite and gastric emptying
Foundayo® binds to and activates the GLP-1 receptor in the brain and gut. This reduces appetite, slows how quickly your stomach empties, and supports glucose regulation. The result is smaller portions feeling more satisfying, longer-lasting fullness between meals, and gradual weight loss.
- 1
Reduces appetite
Activates GLP-1 receptors in the brain that govern hunger and satiety.
- 2
Slows gastric emptying
Food stays in the stomach longer, extending the feeling of fullness.
Eligibility
Who Foundayo is for
Generally a good fit for
- Adults with a BMI of 30 or higher, or 27+ with a weight-related health condition
- Patients who prefer a daily pill over weekly injections
- People who travel often and want a treatment without refrigeration requirements
- Adults with type 2 diabetes seeking weight loss and better glycemic control
Not appropriate for
- Pregnancy, planning pregnancy, or breastfeeding
- Personal or family history of medullary thyroid carcinoma or MEN 2
- History of pancreatitis or severe gastrointestinal disease
- Known hypersensitivity to orforglipron or its components
- Patients relying on oral contraceptives without backup birth control — Foundayo® can reduce the effectiveness of oral birth control for ~30 days after starting and after each dose increase
Calculate your BMI
A starting point your provider considers alongside your full health profile.
BMI is a screening tool, not a diagnosis. Your provider will review your full health profile during the intake to determine eligibility.
Your BMI
—
Journey
What to expect & when
Weeks 1–4
- Smaller appetite and earlier fullness
- Possible mild nausea, constipation, or reflux as your body adjusts
Weeks 5–12
- Cravings continue to ease for most patients
- Steady weight loss as the dose titrates upward
Months 3+
- Continued weight loss for many patients
- Improvements in metabolic markers are common with sustained use
Ongoing
- Continued monitoring, dose adjustments, and cycling decisions guided by your PreventiveMD provider
Side effects
Safety & side effects
Foundayo® shares the gastrointestinal side-effect profile of the GLP-1 class. Most effects are most noticeable around dose increases and ease with time.
Common
- Nausea, especially during titration
- Diarrhea or constipation
- Bloating or reflux
- Decreased appetite
- Mild headache
Less common but serious
- Pancreatitis — severe, persistent abdominal pain
- Gallbladder disease, including gallstones
- Kidney injury from dehydration related to GI side effects
- Possible thyroid C-cell tumors (class warning based on rodent studies)
If you have questions about whether Foundayo is right for you, your PreventiveMD provider will review your full health history once you get started.
Dosing
How to take Foundayo
Foundayo® is taken as one tablet by mouth once daily. The standard titration starts at 0.8 mg, then steps up to 2.5 mg, 5.5 mg, 9 mg, 14.5 mg, and a maintenance dose of up to 17.2 mg — with at least 30 days at each level based on response and tolerability. Your provider chooses the maintenance dose that works best for you. Specific dose is set by your provider based on goals and tolerance.
How to take
- 1Take at roughly the same time each day; food and water timing are flexible.
- 2Swallow the tablet whole — do not split, crush, or chew.
- 3If you use oral birth control, your provider may recommend a backup method for ~30 days after starting Foundayo® and after each dose increase.
- 4If you miss a dose, follow the instructions on your prescription label or contact your provider. Do not double up.
Pricing
Transparent pricing, no surprises
Loading pricing…
FAQs
In case you were wondering
Foundayo® is a daily pill rather than a weekly injection, and it does not require refrigeration. It works through the same GLP-1 pathway and is expected to produce comparable side-effect categories. Average weight loss across the class can vary by drug and dose.
Most patients notice appetite changes within the first few weeks. Visible weight loss typically begins within a couple of months and continues with consistent use. Pace varies by person.
Coverage depends on your plan, your indication, and current manufacturer pricing programs. Our team can help you check coverage and any available savings options before you start.
Many patients can transition between GLP-1 therapies under provider supervision. Your provider will tailor the timing so you avoid overlapping doses or gaps.
Our content is reviewed by our medical team and draws from peer-reviewed clinical research, FDA prescribing information, and recognized clinical guidelines. The primary sources cited on this page:
- [TODO: Pivotal clinical trial citation for Foundayo]
[TODO: Authors, journal, year (DOI when available)]
- [TODO: Mechanism of action / review article]
[TODO: Authors, journal, year (DOI when available)]
- [TODO: FDA prescribing information / regulatory source]
- [TODO: Clinical society guideline or consensus statement]
How to get started
Preventive care begins here
Hi, I’m Eve, your care concierge. Ready to start when you are.
Currently, we are not yet available in Alaska, Kentucky, Louisiana, Mississippi, New Jersey, New Mexico, Rhode Island, and West Virginia. Get notified once we are.
Complete a 5-minute questionnaire
Choose your protocols
Self-pay checkout
Your provider prescribes if it’s the right fit
By starting, you agree to our Terms of Use and acknowledge our Privacy Policy.
